These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 19009659

  • 1. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK.
    World J Gastroenterol; 2008 Nov 07; 14(41):6401-7. PubMed ID: 19009659
    [Abstract] [Full Text] [Related]

  • 2. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, Ma Y, Wuren T, Ge RL.
    J Cancer Res Ther; 2013 Nov 07; 9(3):410-5. PubMed ID: 24125975
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH, Hua D, Du X.
    Cancer Chemother Pharmacol; 2009 Oct 07; 64(5):1001-7. PubMed ID: 19247656
    [Abstract] [Full Text] [Related]

  • 6. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug 07; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

  • 7. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB, Salem SE, Abdelrahim ME, Said AS, Salahuddin A, Hussein MM, Bahnassy AA.
    Exp Mol Pathol; 2017 Feb 07; 102(1):78-85. PubMed ID: 28088319
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J, Luo M, Cui J, Zhou S.
    Int J Clin Exp Pathol; 2015 Feb 07; 8(11):15065-71. PubMed ID: 26823845
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J, Li QF, Yao RY, Lü HY, Jiang J, Sun YY, Song SA, Jiang T.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 07; 32(7):515-9. PubMed ID: 21029695
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.
    Clin Cancer Res; 2005 Sep 01; 11(17):6212-7. PubMed ID: 16144923
    [Abstract] [Full Text] [Related]

  • 16. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ.
    J Clin Oncol; 2001 Dec 01; 19(23):4298-304. PubMed ID: 11731512
    [Abstract] [Full Text] [Related]

  • 17. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.
    Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS.
    J Clin Oncol; 2020 Feb 10; 38(5):472-479. PubMed ID: 31815582
    [Abstract] [Full Text] [Related]

  • 18. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH, Li GY, Wu XJ, Zhang CX, Zhang CF, Zhu KX.
    Int J Clin Exp Pathol; 2015 Feb 10; 8(5):5563-9. PubMed ID: 26191265
    [Abstract] [Full Text] [Related]

  • 19. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
    Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B.
    Br J Cancer; 2008 Apr 22; 98(8):1398-402. PubMed ID: 18362936
    [Abstract] [Full Text] [Related]

  • 20. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X, Xiao S, Jin C, van der Straaten T, Li X.
    J Clin Lab Anal; 2012 Jan 22; 26(1):10-5. PubMed ID: 24833529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.